UNITED STATES ~~SECURITIES~~ ~~AND EXCHANGE COMMISSION~~

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

~~Pursuant~~PURSUANT toTO ~~Section~~ SECTION 13 OR 15(d) OfOF ~~The Securities Exchange Act Of 1934~~THE

~~Date~~SECURITIES ofEXCHANGE ~~Report~~ACT ~~(Date~~OF ~~of earliest event reported): July 10, 2014~~1934

FVDate ~~Pharma~~of ~~International~~Report ~~Corp.~~(Date of earliest event reported): February 24, 2015

FV PHARMA INTERNATIONAL CORP.

(Exact name of registrant as specified in its charter)

Nevada	333-187669	68-0682594
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

203 – 29 Gervais Drive

Toronto, Ontario, Canada M3C 1Y9

(Address of principal executive offices ~~and zip code~~)

(416) 444-4427 ~~(Registrant’s telephone number, including area code)~~

~~Alphala Corp.~~ (~~Former~~Registrant’s ~~name,~~telephone ~~former address and former fiscal year~~number, ifincluding area ~~changed since last report~~code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 54.0302 ~~Amendments~~Non-Reliance toon ~~Articles~~Previously ofIssued ~~Incorporation~~Financial ofStatements ~~Bylaws;~~or ~~Change~~a inRelated ~~Fiscal~~Audit ~~Year~~Report or Completed Interim Review

On ~~July~~February 1018, ~~2014~~2015, ~~Alphala~~FV Pharma International Corp. (the “Company”) filed atwo ~~Certificate~~quarterly ofreports ~~Amendment~~on toForm ~~its~~10-Q ~~Articles~~for ofthe ~~Incorporation~~periods ended July 31, 2014 and October 31, 2014 (the “~~Amendment~~Quarterly Reports”) with the ~~State~~Securities ofand ~~Nevada~~Exchange toCommission ~~change~~(the “SEC”). These filings were ~~its~~completed ~~corporate~~without ~~name~~the ~~from~~consent ~~“Alphala~~of ~~Corp”~~the toCompany’s ~~“FV~~independent ~~Pharma~~registered ~~International~~public ~~Corp~~accounting firm, Cutler & Co., LLC (the “Auditors” A), ~~copy~~as the Company did not request the Auditors to undertake a review of the ~~Amendment~~interim financial statements isincluded ~~attached~~in tothe ~~this~~Quarterly ~~Current~~Reports ~~Report~~using onprofessional ~~Form~~standards ~~8-K~~and procedures conducted for such reviews as ~~Exhibit~~established 3by generally accepted auditing standards.1 The Company’s sole officer and director and the Auditors have therefore determined that the financial statements included in the Quarterly Reports should not be relied upon.

The ~~Company~~Auditors ~~informed~~notified the ~~Financial~~Company ~~Industry~~on February ~~Regulatory~~24, ~~Authority~~2015 ~~(“FINRA”)~~that ofaction ~~such~~should ~~corporate~~be ~~name~~taken ~~change~~to ~~and~~prevent ~~requested~~future areliance ~~symbol~~on ~~change~~the ~~from~~interim ~~“ALPC” to~~financial ~~“FVPI”~~statements ~~corresponding~~included toin the ~~corporate~~Quarterly ~~name~~Reports and ~~change.~~requested Onthat ~~August~~the 5,Quarterly ~~2014,~~Reports ~~FINRA~~be ~~announced~~amended; the ~~corporate~~Company ~~name~~is ~~change and~~currently ~~symbol~~planning ~~change~~to ~~and~~do ~~both~~so ~~corporate~~with ~~actions~~proper authorization ~~took~~from ~~effect~~the ~~on August 6, 2014~~Auditors.

~~Item~~The ~~9.01~~Company ~~Financial~~has ~~Statements~~provided the Auditors with a copy of this Form 8-K and ~~Exhibits~~has requested that the Auditors furnish the Company with a letter addressed to the SEC stating whether the Auditors agree with statements contained herein and, if not, stating the respects in which they do not agree. A copy of this letter is included as Exhibit 16.1 hereto.

(d) Exhibits

Exhibit Number		Exhibit Description
16.1		Letter from Cutler & Co., LLC dated February 26, 2015

Exhibit No.		Description
3.1		Certificate of Amendment

SIGNATURES

~~SIGNATURES~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 26, 2015	FV Pharma International Corp.

	By:	/s/ Shaikh M. Shami
		Shaikh M. Shami
		President, Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, Secretary, Treasurer, Director

Date: August 12, 2014	FV Pharma International Corp.
	By:	/s/ Shaikh M. Shami
		Shaikh M. Shami
		President, Chief Executive Officer, Chief Financial Officer and Chief Accounting Officer,

Filing Compare · FV Pharma International Corp.